We could not find any results for:
Make sure your spelling is correct or try broadening your search.
BriaCell Therapeutics Corp is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell, in collaboration with Incyte Corp., is conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a Combination Study with I... BriaCell Therapeutics Corp is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell, in collaboration with Incyte Corp., is conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a Combination Study with Incyte drugs, INCMGA00012, and epacadostat, in advanced breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing and is designed to produce a potent and selective immune response against the cancer of each patient eliminating the time, expense and complex manufacturing logistics associated with immunotherapies. Show more
Progression free survival (PFS) extended to 9.1 months in ADC resistant patient - quadruple the PFS of patients in similar studiesΒ 1, 2,Β 3Significant reduction of βEye-Bulgingβ metastatic breast...
BriaCell doubles Progression-Free-Survival (PFS) and Clinical Benefit Rate vs historical results in the literatureBria-IMTβ’ PFS compares favorably to PFS of most recent treatment in 48% of...
PHILADELPHIA and VANCOUVER, British Columbia, May 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) (βBriaCellβ or the βCompanyβ), a clinical-stage...
Study to evaluate the effects of Bria-OTSβ’ in combination with anti-PD-1 antibody tislelizumab, in advanced, late stage, heavily pretreated metastatic breast cancer. PHILADELPHIA and VANCOUVER...
83% intracranial objective response rate (iORR) with Bria-IMTβ’ in heavily pretreated advanced breast cancer patients with CNS metastasesMedian progression free survival (PFS) of 4.1 months in ADC...
PHILADELPHIA and VANCOUVER, British Columbia, May 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (βBriaCellβ or the βCompanyβ), a clinical-stage...
PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (βBriaCellβ or the βCompanyβ), a clinical-stage...
Oral presentation by Mayo Clinic Professor and Principal Investigator, Saranya Chumsri, MDTwo poster presentations include Drs. Hurvitz (Fred Hutchinson Cancer Center), Brufsky (UPMC), and...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.23 | -22.7722772277 | 1.01 | 1.03 | 0.72 | 201486 | 0.92114405 | CS |
4 | -0.56 | -41.7910447761 | 1.34 | 1.39 | 0.72 | 137559 | 1.01305252 | CS |
12 | -1.39 | -64.0552995392 | 2.17 | 2.44 | 0.72 | 141771 | 1.35550262 | CS |
26 | -3.65 | -82.3927765237 | 4.43 | 4.61 | 0.72 | 110367 | 2.11987438 | CS |
52 | -5.87 | -88.2706766917 | 6.65 | 7.59 | 0.72 | 104307 | 3.70055891 | CS |
156 | -3.98 | -83.6134453782 | 4.76 | 12.47 | 0.72 | 535310 | 7.35016248 | CS |
260 | -3.46 | -81.6037735849 | 4.24 | 12.47 | 0.72 | 841622 | 6.55785448 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions